Start with a free account for 3 free CME credits. Already a subscriber? Sign in.

Paper Chase #4 | Risks/benefits of Direct Oral Anticoagulants versus Warfarin

Matthew DeLaney, MD, FACEP, FAAEM and Matthieu DeClerck, MD
00:00
03:24
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

BOTTOM LINE: Overall, apixaban was found to be the safest drug, with reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin. Rivaroxaban and low dose apixaban were associated with increased risks of all cause mortality compared with warfarin.

To view chapter written summaries, you need to subscribe.

Sign up today for full access to all episodes.

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.
Clots and OCP's Full episode audio for MD edition 177:43 min - 83 MB - M4APrimary Care RAP December 2018 Written Summary 520 KB - PDF

To earn CME for this chapter, you need to subscribe.

Sign up today for full access to all episodes and earn CME.

0.25 Free AMA PRA Category 1 Credits™ certified by Hippo Education or 0.25 Free prescribed credits by the American Academy of Family Physicians

  1. Complete Quiz
  2. Complete Evaluation
  3. Print Certificate

3.25 AMA PRA Category 1 Credits™ certified by Hippo Education or 3.25 prescribed credits by the American Academy of Family Physicians

  1. Complete Quiz
  2. Complete Evaluation
  3. Print Certificate